Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q2 2025 · 10-Q
Revenue$391.00K$391.00K+19.9% vs Q2 2024 Net Income-$798.00K-$798.00KN/M vs Q2 2024 EPS Diluted-$0.01-$0.01N/M vs Q2 2024 Gross Profit$227,000+28.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$544,000N/M Margins · derivedGross margin58.1%+3.8 pt vs Q2 2024
Operating margin-185.4%+110.3 pt vs Q2 2024
Net margin-204.1%+103.3 pt vs Q2 2024
ended Jan 31, 2025 · filed Mar 17, 2025 · 45 d after period end